DelveInsight’s ‘Cervical Cancer –Market Insights, Epidemiology, and Market Forecast-2030’ report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology as well as the market trends of Cervical Cancer in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
The Cervical Cancer market report provides analysis regarding current treatment practices, emerging drugs like Cemiplimab, Durvalumab, LN-145, Z-100, Tisotumab vedotin, promising therapies, market share of the individual therapies, and historical, current and forecasted Cervical Cancer market size from 2017 to 2030, segmented by seven major markets.
The report also covers current Cervical Cancer treatment practice/algorithm, guidelines, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities. It assesses the underlying potential of the market.
Geography Covered
• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan
Study Period: 2017–2030
Cervical Cancer – Disease Understanding and Treatment Algorithm
Overview:
Cervical cancer is one of the most common gynecological tumors that occur in the cells of the cervix. The most significant cause of cervical cancer is persistent papillomavirus infection. Gynecological cancers are among the most common cancers in women. Cervical cancer is the most common type of gynecological cancer. Indeed, it is one of the major public health problems in the world and one of the top causes for disability-adjusted life-years (DALYs). Yet, cervical cancer is one of the most preventable cancers. HPV is the most common sexually transmitted infection worldwide and is the cause of almost all cases of cervical cancer. Because precancerous lesions can be found by the Papanicolaou (Pap) test and treated and cured, cervical cancer is often detected before it becomes advanced.
Treatment:
The standard management of patients with early‐stage (FIGO stage IA‐IB1) cervical cancer is a radical hysterectomy and lymph node dissection and/or radiation with or without chemotherapy. The standard management of individuals with locally advanced cervical cancer includes external beam radiotherapy with concurrent cisplatin‐based chemotherapy with brachytherapy.
This chapter covers the details of conventional and current medical therapies available for the treatment of Cervical Cancer. It also provides Cervical Cancer treatment guidelines across the United States, Europe, and Japan.
DelveInsight’s Cervical Cancer market report gives a thorough understanding of the disease by including details such as disease definition, symptoms, types, grading, pathophysiology, and diagnosis. It also provides Cervical Cancer treatment algorithms and treatment guidelines in the US, Europe, and Japan.
Epidemiology:
The Cervical Cancer epidemiology chapters provide insights about historical and current Cervical Cancer patient pool and forecasted trends for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. Cervical Cancer epidemiology is segmented by the Incident cases of Cervical Cancer, Stage-specific Incidence of Cervical Cancer, Histopathologic Types of Cervical Cancer, Age-specific cases of Cervical Cancer. Besides, the report includes a thorough analysis of all segments.
According to DelveInsight’s, the total prevalent population of Cervical Cancer in seven major markets was 43,514 in 2017. These cases are expected to increase with a significant CAGR during the study period (2017–2030).
Among all the seven major markets, total prevalent cases for Cervical Cancer were highest in the United States, followed by Japan and Germany. Spain accounted for the least number of prevalent cases among the 7MM.
Drug Chapters:
This segment encloses the detailed analysis of the drugs in the Cervical Cancer pipeline. It also helps understand the cervical cancer clinical trial details, expressive pharmacological action, agreements of the included drug, and the latest news and press releases.
Therapies administered for treatment of metastatic or recurrent cases comprises systemic therapies, which include paclitaxel plus cisplatin-based doublets or triplet combination therapies. Over the past three decades, these have remained the mainstay or standard of care (SOC) without vastly impacting the median overall survival (OS) of patients with stage IVB or recurrent disease despite multiple studies with single-agent or combination chemotherapy. FDA approved drugs include Avastin, Keytruda and Hycamtin.
Market Outlook:
The market size of Cervical Cancer is expected to increase at a significant CAGR during the study period (2017–2030). Among all the seven major markets, the United States accounted for the largest Cervical Cancer market size. Among EU5 countries, Germany, in 2017, had the largest market size with USD 25.46 million, while Spain had the smallest market size of USD 0.34 million.
Drugs Uptake:
This section focuses on the rate of uptake of the potential drugs in the Cervical Cancer market or expected to get launched in the market during the study period 2017–2030. The analysis covers Cervical Cancer market uptake by drugs; patient uptake by therapies; and sale of each drug.
It helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs based on market share and size. All of which will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Cemiplimab (Regeneron), Durvalumab (AstraZeneca), LN-145 (Iovance), Z-100 (Zeria Pharmaceutical), Tisotumab vedotin (Seattle Genetics/Genmab) are the major players that are going to alter the market dynamics in the coming years, during the forecasted period 2020-2030.
Cervical Cancer: Pipeline Development Activities
The report provides insights into different therapeutic candidates and also analyses the key players involved in developing targeted therapeutics.
Pipeline Development Activities:
The report covers the detailed information of collaborations, acquisition and merger, licensing, patent details, and emerging therapies, concerning Cervical Cancer .
KOL Views
To keep up with current market trends, we take KOLs and SME’s opinion working in Cervical Cancer domain through primary research to fill the data gaps and validate our secondary research. It will support the clients in assessing potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.
Competitive Intelligence Analysis
We have performed the competitive and market Intelligence analysis of the Cervical Cancer Market by using various competitive intelligence tools that include SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies etc. Besides, the inclusion of the analysis entirely depends upon the data availability.
Report Highlights:
• In the coming years, Cervical Cancer market scenario is expected to experience a positive shift across the 7MM due a robust pipeline.
• Our in-depth analysis of the pipeline assets across different stages of development (Phase II and Phase III), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities
Cervical Cancer Report Insights:
• Patient Population
• Therapeutic Approaches
• Cervical Cancer Pipeline Analysis
• Cervical Cancer Market Size and Trends
• Market Opportunities
• Impact of upcoming Therapies
Cervical Cancer Report Key Strengths:
• 11 years Forecast
• 7MM Coverage
• Cervical Cancer Epidemiology Segmentation
• Key Cross Competition
• Market Size by Therapies
• Drugs Uptake
Cervical Cancer Report Assessment:
• Pipeline Product Profiles
• Key Products and Key Players
• Market Drivers and Barriers
Key Questions
Market Insights:
• What was the Cervical Cancer market share (%) distribution in 2017 and how it would look like in 2030?
• What would be the Cervical Cancer total market size as well as market size by therapies across the 7MM during the forecast period (2017–2030)?
• What are the key findings pertaining to the market across 7MM and which country will have the largest Cervical Cancer market size during the forecast period (2017–2030)?
• At what CAGR, the Cervical Cancer market is expected to grow in 7MM during the forecast period (2017–2030)?
• What would be the Cervical Cancer market outlook across the 7MM during the forecast period (2017–2030)?
• What would be the Cervical Cancer market growth till 2030, and what will be the resultant market Size in the year 2030?
• How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends?
Epidemiology Insights:
• What are the disease risk, burden and unmet needs of Cervical Cancer?
• What is the historical Cervical Cancer patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
• What would be the forecasted patient pool of Cervical Cancer in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
• What will be the growth opportunities in the 7MM concerning the patient population pertaining to Cervical Cancer?
• Out of all 7MM countries, which country would have the highest prevalent population of Cervical Cancer during the forecast period (2017–2030)?
• At what CAGR the population is expected to grow in 7MM during the forecast period (2017–2030)?
Current Treatment Scenario, Marketed Drugs and Emerging Therapies:
• What are the current options for the Cervical Cancer treatment, along with the approved therapy?
• What are the current treatment guidelines for the treatment of Cervical Cancer in the USA, Europe, and Japan?
• How many companies are developing therapies for the treatment of Cervical Cancer?
• How many therapies are developed by each company for Cervical Cancer?
• How many are emerging therapies in mid-stage, and late stage of development for Cervical Cancer treatment?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Cervical Cancer therapies?
• What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Cervical Cancer and their status?
• What are the key designations that have been granted for the emerging therapies for Cervical Cancer?
• What is the global historical and forecasted market of Cervical Cancer?
Reasons to buy:
• The report will help in developing business strategies by understanding trends shaping and driving the Cervical Cancer market
• To understand the future market competition in the Cervical Cancer market and Insightful review of the key market drivers and barriers
• Organize sales and marketing efforts by identifying the best opportunities for Cervical Cancer in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
• Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
• Organize sales and marketing efforts by identifying the best opportunities for Cervical Cancer market
• To understand the future market competition in the Cervical Cancer market
Which geography accounted for the largest Cervical Cancer market size?
The United States accounted for the largest Cervical Cancer market size.
What is forecasted Cervical Cancer size in 2030?
DelveInsight estimates an increase in Cervical Cancer Market Size during the study period, 2017–2030
What are the present Cervical Cancer market drivers?
Advancements in treatment, improvement in preventive measures, early detection of disease, therapies in development for recurrent and relapsed cases,
What are the Cervical Cancer market barriers?
Insufficient data on disease biomarkers, barriers in screening, access to palliative care, costs associated with treatment
How many companies are developing drugs for Cervical Cancer?
Currently, six key pharma players are developing the drug for Cervical Cancer
Which are the leading companies in Cervical Cancer market?
Key Players – Regeneron, AstraZeneca, LN-145, Zeria Pharmaceutical, Seattle Genetics/Genmab, Advaxis
How is epidemiology segmented for Cervical Cancer?
Incident cases of Cervical Cancer, Stage-specific Incidence of Cervical Cancer, Histopathologic Types of Cervical Cancer, Age-specific cases of Cervical Cancer
'
1 Key Insights
2 Executive Summary of Cervical Cancer
3 SWOT Analysis for Cervical Cancer
4 Cervical Cancer Epidemiology Overview at a Glance
4.1 Patient Share (%) Distribution of Cervical Cancer in 2017
4.2 Patient Share (%) Distribution of Cervical Cancer in 2030
5 Cervical Cancer Market Overview at a Glance
5.1 Market Share (%) Distribution of Cervical Cancer in 2017
5.2 Market Share (%) Distribution of Cervical Cancer in 2030
6 Disease Background and Overview
6.1 Introduction
6.2 Definition
6.3 Etiology
6.4 Risk factors
6.5 Staging
6.6 Pathophysiology
6.7 Diagnosis
Forty-year timeline of public health research and policy on HPV and cervical cancer
7 Epidemiology and Patient Population
7.1 Key Findings
7.2 Total Incident Population of Cervical Cancer in 7MM
7.3 Assumption and Rationale: 7MM
8 Country Wise-Epidemiology of Cervical Cancer
8.1 The United States
8.1.1 Incident cases of Cervical Cancer in the United States
8.1.2 Stage-specific Incidence of Cervical Cancer in the United States
8.1.3 Histopathologic Types of Cervical Cancer in the United States
8.1.4 Age-specific cases of Cervical Cancer in the United States
8.2 Germany
8.2.1 Incident cases of Cervical Cancer in Germany
8.2.2 Stage-specific Incidence of Cervical Cancer in Germany
8.2.3 Histopathologic Types of Cervical Cancer in Germany
8.2.4 Age-specific cases of Cervical Cancer in Germany
8.3 France
8.3.1 Incident cases of Cervical Cancer in France
8.3.2 Stage-specific Incidence of Cervical Cancer in France
8.3.3 Histopathologic Types of Cervical Cancer in France
8.3.4 Age-specific cases of Cervical Cancer in France
8.4 Italy
8.4.1 Incident cases of Cervical Cancer in Italy
8.4.2 Stage-specific Incidence of Cervical Cancer in Italy
8.4.3 Histopathologic Types of Cervical Cancer in Italy
8.4.4 Age-specific cases of Cervical Cancer in Italy
8.5 Spain
8.5.1 Incident cases of Cervical Cancer in Spain
8.5.2 Stage-specific Incidence of Cervical Cancer in Spain
8.5.3 Histopathologic Types of Cervical Cancer in Spain
8.5.4 Age-specific cases of Cervical Cancer in Spain
8.6 The United Kingdom
8.6.1 Incident cases of Cervical Cancer in the United Kingdom
8.6.2 Stage-specific Incidence of Cervical Cancer in the United Kingdom
8.6.3 Histopathologic Types of Cervical Cancer in the United Kingdom
8.6.4 Age-specific cases of Cervical Cancer in the United Kingdom
8.7 Japan
8.7.1 Incident cases of Cervical Cancer in Japan
8.7.2 Stage-specific Incidence of Cervical Cancer in Japan
8.7.3 Histopathologic Types of Cervical Cancer in Japan
8.7.4 Age-specific cases of Cervical Cancer in Japan
9 Treatment and Management
9.1 Side effects of treatment
9.2 Prevention of Cervical cancer
9.3 Guidelines
9.3.1 NCCN Guidelines
9.3.2 ESMO guidelines
9.3.3 Japan Society of Gynecologic Oncology (JSGO) Guidelines
9.4 Patient Journey
10 Unmet Needs
11 Marketed Therapies
11.1 Avastin (Bevacizumab): Genentech/Roche
11.1.1 Product Description
11.1.2 Regulatory Milestones
11.1.3 Other developmental activities
11.1.4 Clinical Development
11.1.4.1 Clinical Trials Information
11.1.5 Safety and Efficacy
11.1.6 Product Profile
11.2 Avastin Biosimilars
11.2.1 Mvasi: Amgen/Allergan
11.2.1.1 Product Description
11.2.1.2 Regulatory Milestones
11.2.1.3 Other developmental activities
11.2.2 Zirabev: Pfizer
11.2.2.1 Product Description
11.2.2.2 Regulatory Milestones
11.2.3 Aybintio: Samsung Bioepis
11.2.3.1 Product Description
11.2.3.2 Regulatory Milestones
11.3 Hycamtin (Topotecan Hydrochloride): GlaxoSmithKline/Novartis
11.3.1 Product Description
11.3.2 Regulatory Milestones
11.3.3 Other developmental activities
11.3.4 Clinical Development
11.3.4.1 Clinical Trials Information
11.3.5 Safety and Efficacy
11.3.6 Product Profile
11.4 Keytruda (Pembrolizumab): Merck Sharp & Dohme
11.4.1 Product Description
11.4.2 Regulatory Milestones
11.4.3 Clinical Development
11.4.3.1 Clinical Trials Information
11.4.4 Safety and Efficacy
11.4.5 Product Profile
12 Emerging Therapies
12.1 Tisotumab vedotin: Seattle Genetics/ Genmab
12.1.1 Product Description
12.1.2 Product Development Activities
12.1.3 Clinical Development
12.1.3.1 Clinical Trial Information
12.1.4 Safety and Efficacy
12.2 Durvalumab: AstraZeneca
12.2.1 Product Description
12.2.2 Product Development Activities
12.2.3 Clinical Development
12.2.3.1 Clinical Trial Information
12.3 Z-100: Zeria Pharmaceutical
12.3.1 Product Description
12.3.2 Clinical Development
12.3.2.1 Clinical Trial Information
12.3.3 Safety and Efficacy
12.4 Cemiplimab: Regeneron Pharmaceutical/Sanofi
12.4.1 Product Description
12.4.2 Product Development Activities
12.4.3 Clinical Development
12.4.3.1 Clinical Trial Information
12.4.4 Safety and Efficacy
12.5 ADXS11-001: Advaxis
12.5.1 Product Description
12.5.2 Product Development Activities
12.5.3 Clinical Development
12.5.3.1 Clinical Trial Information
12.6 LN-145: Iovance Biotherapeutics
12.6.1 Product Description
12.6.2 Product Development Activities
12.6.3 Clinical Development
12.6.3.1 Clinical Trial Information
12.6.4 Safety and Efficacy
13 Other Promising Therapies
13.1 Balstilimab + Zalifrelimab: Agenus
13.1.1 Product Description
13.1.2 Product Development Activities
13.1.3 Clinical Development
13.1.3.1 Clinical Trial Information
13.1.4 Safety and Efficacy
13.2 Tiragolumab: Roche
13.2.1 Product Description
13.3 AK104: Akeso Biopharma
13.3.1 Product Description
13.4 Trastuzumab Deruxtecan: AstraZeneca
13.4.1 Product Description
13.5 VB10.16 + Atezolizumab: Vaccibody/ Roche
13.5.1 Product Description
13.6 RO6874281: Roche
13.6.1 Product Description
13.7 ALT 803: Altor BioScience
13.7.1 Product Description
13.8 Balstilimab: Agenus
13.8.1 Product Description
14 Cervical Cancer: 7 Major Market Analysis
14.1 Key Findings
14.2 Market Size of Cervical Cancer in 7MM
14.3 Market Outlook – 7MM
15 Country-Wise Market Analysis
15.1 The United States
15.1.1 Total Market size of Cervical Cancer
15.1.2 Cervical Cancer Market Size by Therapies
15.1.2.1 Market Size of Therapies for Locally Advanced Cervical Cancer
15.1.2.2 Market Size of Metastatic Cervical Cancer by 1st LoT
15.1.2.3 Market Size of Metastatic Cervical Cancer by 2nd LoT
15.2 EU5 Countries
15.2.1 Germany
15.2.1.1 Total Market size of Cervical Cancer
15.2.1.2 Cervical Cancer Market Size by Therapies
15.2.1.2.1 Market Size of Therapies for Locally Advanced Cervical Cancer
15.2.1.2.2 Market Size of Metastatic Cervical Cancer by 1st LoT
15.2.1.2.3 Market Size of Metastatic Cervical Cancer by 2nd LoT
15.2.2 France
15.2.2.1 Total Market size of Cervical Cancer
15.2.2.2 Cervical Cancer Market Size by Therapies
15.2.2.2.1 Market Size of Therapies for Locally Advanced Cervical Cancer
15.2.2.2.2 Market Size of Metastatic Cervical Cancer by 1st LoT
15.2.2.2.3 Market Size of Metastatic Cervical Cancer by 2nd LoT
15.2.3 Italy
15.2.3.1 Total Market size of Cervical Cancer
15.2.3.2 Cervical Cancer Market Size by Therapies
15.2.3.2.1 Market Size of Therapies for Locally Advanced Cervical Cancer
15.2.3.2.2 Market Size of Metastatic Cervical Cancer by 1st LoT
15.2.3.2.3 Market Size of Metastatic Cervical Cancer by 2nd LoT
15.2.4 Spain
15.2.4.1 Total Market size of Cervical Cancer
15.2.4.2 Cervical Cancer Market Size by Therapies
15.2.4.2.1 Market Size of Therapies for Locally Advanced Cervical Cancer
15.2.4.2.2 Market Size of Metastatic Cervical Cancer by 1st LoT
15.2.4.2.3 Market Size of Metastatic Cervical Cancer by 2nd LoT
15.2.5 The UK
15.2.5.1 Total Market size of Cervical Cancer
15.2.5.2 Cervical Cancer Market Size by Therapies
15.2.5.2.1 Market Size of Therapies for Locally Advanced Cervical Cancer
15.2.5.2.2 Market Size of Metastatic Cervical Cancer by 1st LoT
15.2.5.2.3 Market Size of Metastatic Cervical Cancer by 2nd LoT
15.3 Japan
15.3.1 Total Market size of Cervical Cancer
15.3.2 Cervical Cancer Market Size by Therapies
15.3.2.1 Market Size of Therapies for Locally Advanced Cervical Cancer
15.3.2.2 Market Size of Metastatic Cervical Cancer by 1st LoT
15.3.2.3 Market Size of Metastatic Cervical Cancer by 2nd LoT
16 Market Drivers
17 Market Barriers
18 Appendix
18.1 Report Methodology
19 DelveInsight Capabilities
20 Disclaimer
21 About DelveInsight
Table 1: Summary of Cervical Cancer Market, Epidemiology, and Key Events (2017–2030)
Table 2: Total cases of Cervical Cancer in 7MM (2017-2030)
Table 3: Incident cases of Cervical Cancer in the United States (2017-2030)
Table 4: Stage Specific Incidence of Cervical Cancer in the United States(2017-2030)
Table 5: Histopathologic Types of Cervical Cancer in the United States(2017-2030)
Table 6: Age specific cases of Cervical Cancer in the United States(2017-2030)
Table 7: Incident cases of Cervical Cancer in Germany (2017-2030)
Table 8: Stage Specific Incidence of Cervical Cancer in Germany(2017-2030)
Table 9: Histopathologic Types of Cervical Cancer in Germany(2017-2030)
Table 10: Age specific cases of Cervical Cancer in Germany(2017-2030)
Table 11: Incident cases of Cervical Cancer in France (2017-2030)
Table 12: Stage Specific Incidence of Cervical Cancer in France(2017-2030)
Table 13: Histopathologic Types of Cervical Cancer in France(2017-2030)
Table 14: Age specific cases of Cervical Cancer in France(2017-2030)
Table 15: Incident cases of Cervical Cancer in Italy (2017-2030)
Table 16: Stage Specific Incidence of Cervical Cancer in Italy(2017-2030)
Table 17: Histopathologic Types of Cervical Cancer in Italy(2017-2030)
Table 18: Age specific cases of Cervical Cancer in Italy(2017-2030)
Table 19: Incident cases of Cervical Cancer in Spain (2017-2030)
Table 20: Stage Specific Incidence of Cervical Cancer in Spain(2017-2030)
Table 21: Histopathologic Types of Cervical Cancer in Spain(2017-2030)
Table 22: Age specific cases of Cervical Cancer in Spain(2017-2030)
Table 23: Incident cases of Cervical Cancer in the United Kingdom (2017-2030)
Table 24: Stage Specific Incidence of Cervical Cancer in the United Kingdom(2017-2030)
Table 25: Histopathologic Types of Cervical Cancer in the United Kingdom(2017-2030)
Table 26: Age specific cases of Cervical Cancer in the United Kingdom(2017-2030)
Table 27: Incident cases of Cervical Cancer in Japan (2017-2030)
Table 28: Stage Specific Incidence of Cervical Cancer in Japan(2017-2030)
Table 29: Histopathologic Types of Cervical Cancer in Japan(2017-2030)
Table 30: Age specific cases of Cervical Cancer in Japan(2017-2030)
Table 31: Avastin, Clinical Trial Description, 2020
Table 32: Hycamtin, Clinical Trial Description, 2020
Table 33: Keytruda, Clinical Trial Description, 2020
Table 34: Tisotumab Vedotin , Clinical Trial Description, 2020
Table 35: Z-100, Clinical Trial Description, 2020
Table 36: Cemiplimab , Clinical Trial Description, 2020
Table 37: ADXS11-001, Clinical Trial Description, 2020
Table 38: LN-145 , Clinical Trial Description, 2020
Table 39: Balstilimab + Zalifrelimab, Clinical Trial Description, 2020
Table 40: 7 Major Market Size of Cervical Cancer in USD Million (2017–2030)
Table 41: The US Market size of Cervical Cancer in USD Million (2017–2030)
Table 42: The US market size of Therapies for Locally Advanced Cervical Cancer in USD Million (2017–2030)
Table 43: The US market size of Metastatic Cervical Cancer by 1st LoT in USD Million (2017–2030)
Table 44: The US market size of Metastatic Cervical Cancer by 2nd LoT in USD Million (2017–2030)
Table 45: Germany Market size of Cervical Cancer in USD Million (2017–2030)
Table 46: Germany market size of Therapies for Locally Advanced Cervical Cancer in USD Million (2017–2030)
Table 47: Germany market size of Metastatic Cervical Cancer by 1st LoT in USD Million (2017–2030)
Table 48: Germany market size of Metastatic Cervical Cancer by 2nd LoT in USD Million (2017–2030)
Table 49: France Market size of Cervical Cancer in USD Million (2017–2030)
Table 50: France market size of Therapies for Locally Advanced Cervical Cancer in USD Million (2017–2030)
Table 51: France market size of Metastatic Cervical Cancer by 1st LoT in USD Million (2017–2030)
Table 52: France market size of Cervical Cancer by Therapies in USD Million (2017–2030)
Table 53: Italy Market size of Cervical Cancer in USD Million (2017–2030)
Table 54: Italy market size of Therapies for Locally Advanced Cervical Cancer in USD Million (2017–2030)
Table 55: Italy market size of Metastatic Cervical Cancer by 1st LoT in USD Million (2017–2030)
Table 56: Italy market size of Metastatic Cervical Cancer by 2nd LoT in USD Million (2017–2030)
Table 57: Spain Market size of Cervical Cancer in USD Million (2017–2030)
Table 58: Spain market size of Therapies for Locally Advanced Cervical Cancer in USD Million (2017–2030)
Table 59: Spain market size of Metastatic Cervical Cancer by 1st LoT in USD Million (2017–2030)
Table 60: Spain market size of Metastatic Cervical Cancer by 2nd LoT in USD Million (2017–2030)
Table 61: The UK Market size of Cervical Cancer in USD Million (2017–2030)
Table 62: The UK market size of Therapies for Locally Advanced Cervical Cancer in USD Million (2017–2030)
Table 63: The UK market size of Metastatic Cervical Cancer by 1st LoT in USD Million (2017–2030)
Table 64: The UK market size of Metastatic Cervical Cancer by 2nd LoT in USD Million (2017–2030)
Table 65: Japan Market size of Cervical Cancer in USD Million (2017–2030)
Table 66: Japan market size of Therapies for Locally Advanced Cervical Cancer in USD Million (2017–2030)
Table 67: Japan market size of Metastatic Cervical Cancer by 1st LoT in USD Million (2017–2030)
Table 68: Japan market size of Metastatic Cervical Cancer by 2nd LoT in USD Million (2017–2030)
